CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 148 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $492,377 | -46.7% | 78,529 | -70.2% | 0.04% | -59.6% |
| Q3 2022 | $923,000 | +18.6% | 263,529 | 0.0% | 0.10% | -8.3% |
| Q2 2022 | $778,000 | -5.0% | 263,529 | 0.0% | 0.11% | +52.1% |
| Q1 2022 | $819,000 | -8.0% | 263,529 | 0.0% | 0.07% | +39.2% |
| Q4 2021 | $890,000 | -7.5% | 263,529 | 0.0% | 0.05% | +4.1% |
| Q3 2021 | $962,000 | -16.3% | 263,529 | 0.0% | 0.05% | -27.9% |
| Q2 2021 | $1,149,000 | -4.0% | 263,529 | 0.0% | 0.07% | -27.7% |
| Q1 2021 | $1,197,000 | -20.9% | 263,529 | 0.0% | 0.09% | -5.1% |
| Q4 2020 | $1,513,000 | -20.7% | 263,529 | 0.0% | 0.10% | -41.1% |
| Q3 2020 | $1,908,000 | +107.4% | 263,529 | 0.0% | 0.17% | +90.9% |
| Q2 2020 | $920,000 | -1.7% | 263,529 | -58.3% | 0.09% | -3.3% |
| Q1 2020 | $936,000 | -37.8% | 632,387 | -17.7% | 0.09% | -27.2% |
| Q4 2019 | $1,506,000 | -61.7% | 768,142 | 0.0% | 0.12% | -71.3% |
| Q3 2019 | $3,933,000 | -33.7% | 768,142 | -7.9% | 0.44% | +11.2% |
| Q2 2019 | $5,935,000 | -43.4% | 834,096 | +5.3% | 0.39% | -41.1% |
| Q1 2019 | $10,485,000 | +69.1% | 792,096 | 0.0% | 0.67% | +80.0% |
| Q4 2018 | $6,199,000 | +20.4% | 792,096 | +70.8% | 0.37% | +49.8% |
| Q3 2018 | $5,147,000 | – | 463,807 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |